Diego Cadavid - 01 Mar 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Medical Officer
Issuer ticker: XFOR
Reported as of: 01 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Mar 2022, 15:08:48 UTC
Prior SEC filing: 14 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Derek M. Meisner, attorney-in-fact

Key filing fact

Diego Cadavid filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 01 Mar 2022.

Key facts

This page summarizes Diego Cadavid's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Mar 2022, 15:08.

Change

Previous filing in this sequence was filed on 14 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +97,000
Change %: +1365%
Price: $0.000000
Shares after: 104,107
Date: 01 Mar 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

Footnote F2

Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units.